This publication brought together all the major contemporary studies on the topic of treating heroin dependence to address two key questions : does the evidence available now support the use of supervised injectable heroin treatment for those who have failed to respond adequately to other approaches? and if so, what are the clinical management issues necessary to ensure that this therapeutic option can be delivered in a manner that avoids the obvious risks associated with such an intervention?

The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.

"These guidelines were produced by the World Health Organization (WHO), Department of Mental Health and Substance Abuse, in collaboration with the United Nations Office on Drugs and Crime (UNODC) a Guidelines Development Group of technical experts, and in consultation with the International Narcotics Control Board (INCB) secretariat and other WHO departments. WHO also wishes to acknowledge the financial contribution of UNODC and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to this project. " - p. iv

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD)—methadone, naltrexone, and buprenorphine—and provides guidance for healthcare professionals and addiction treatment providers on appropriate prescribing practices for these medications and effective strategies for supporting the patients utilizing medication for the treatment of OUD. The goal of treatment for opioid addiction or OUD is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential. This TIP also educates patients, families, and the general public about how OUD medications work and the benefits they offer. Related products: Medication-Assisted Treatment of Opioid Use Disorder: Pocket Guide A Shared Burden: The Military and Civilian Consequences of Army Pain Management Since 2001 Click our Alcoholism, Smoking & Substance Abuse collection to find more resources on this topic.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

This is the first volume of the long-awaited research report on a much discussed study on the prescription of heroin and other narcotics to chronic heroin addicts in Switzerland. Data were collected over a period of 3 years on a cohort of 1,035 chronic heroin addicts who had failed in drug-free or methadone substitution treatments and who were prescribed heroin, morphine or methadone within the framework of a comprehensive care program. According to the findings of the study, heroin maintenance is considered to have a positive effect on both patients and their social environment due to an improvement in health and social status of the patients as well as a significant decrease in drug-related delinquency. This report provides a unique source of information on pharmacological, medical and psychosocial aspects of heroin maintenance. It is indispensable reading for psychiatrists, doctors, and social workers working with drug addicts as well as for pharmacologists, social scientists, criminologists and public health officials concerned with the treatment and management of drug addiction.

Why medication-assisted treatment, the most effective tool for battling opioid addiction, is significantly underused in the United States. Bronze Winner of the 2021 IPPY Book Award in Health/Medicine/Nutrition, Gold Winner of the 2020 Foreword INDIES Award in Health America's addiction crisis is growing worse. More than 115 Americans die daily from opioid overdoses, with half a million deaths expected in the next decade. Time and again, scientific studies show that medications like Suboxone and methadone are the most reliable and effective treatment, yet more than 60 percent of US addiction treatment centers fail to provide access to them. In The Opioid Fix, Barbara Andraka-Christou highlights both the promise and the underuse of medication-assisted treatment (MAT). Addiction, Andraka-Christou writes, is a chronic medical condition. Why treat it, then, outside of mainstream medicine? Drawing on more than 100 in-depth interviews with people in recovery, their family members, treatment providers, and policy makers, Andraka-Christou reveals a troubling landscape characterized by underregulated treatment centers and unnecessary ideological battles between twelve-step support groups and medication providers. The resistance to MAT—from physicians who won't prescribe it, to drug courts that prohibit it, to politicians who overregulate it—showcases the narrow-mindedness of the system and why it isn't working. Recounting the true stories of people in recovery, this groundbreaking book argues that MAT needs to be available to anyone suffering from opioid addiction. Unlike other books about the opioid crisis, which have largely focused on causal factors like pharmaceutical overprescription and heroin trafficking, this book focuses on people who have already developed an opioid addiction but are struggling to find effective treatment. Validating the experience of hundreds of thousands of Americans, The Opioid Fix sounds a loud call for policy reforms that will help put lifesaving drugs into the hands of those who need them the most.